Epilepsy is associated with disrupted activities in the brain called seizures, which affects the central nervous system. Depending on the area of the brain obstructed by seizures, these are categorized into generalized seizures and partial seizures. Generalized seizures affect the whole brain, while partial seizures affect just one part of the brain. Depending on their severity, seizures are termed as mild seizures and stronger seizures. Mild seizures are difficult to diagnose, as these last for only a few seconds. Stronger seizures may last for a few seconds to a few or several minutes, resulting in spasms and uncontrollable muscle twitches. This may cause the patient to lose consciousness, lead to temporary loss of cognition, or memory loss during the seizure. Pediatric epilepsy can be caused due to a trauma injury, complications during birth, or genetic disorder. Epilepsy that occurs due to brain infections such as meningitis is known as symptomatic epilepsy, while genetics related condition is called idiopathic epilepsy.
Market Analysis and Insights: Global Anti-epileptic Drugs for Pediatrics Market
Prior to COVID-19, the market for Anti-epileptic Drugs for Pediatrics was anticipated to grow from US$ XX million in 2020 to US$ XX million by 2026; it is expected to grow at a CAGR of XX% during 2021–2026, whereas post-COVID-19 scenario, the market for Anti-epileptic Drugs for Pediatrics is projected to grow from US$ XX million in 2020 (a change by ~XX% compared to market estimated for 2020 before the outbreak of COVID-19) to US$ XX billion by 2026; it is expected to grow at a CAGR of XX% during 2021–2026. The solicitation of proposals by the governments and public–private companies across the world to mitigate the impact of the COVID-19 pandemic is the key factor propelling the growth of the Anti-epileptic Drugs for Pediatrics market.
Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost 200 countries around the globe with the World Health Organization declaring it a public health emergency. The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the Anti-epileptic Drugs for Pediatrics market in 2020. The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor events restricted; over forty countries state of emergency declared; massive slowing of the supply chain; stock market volatility; falling business confidence, growing panic among the population, and uncertainty about future.
This report also analyzes the impact of Coronavirus COVID-19 on the Anti-epileptic Drugs for Pediatrics industry.
Global Anti-epileptic Drugs for Pediatrics Scope and Segment
Anti-epileptic Drugs for Pediatrics market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Anti-epileptic Drugs for Pediatrics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on production capacity, revenue and forecast by Type and by Application for the period 2015-2026.
The following manufacturers are covered in this report:
Mylan N.V
Cephalon, Inc
GlaxoSmithKline plc
Janssen Pharmaceuticals
Novartis AG
Pfizer, Inc
Sanofi S.A
UCB Pharma Limited
Sunovion Pharmaceuticals Limited
Valeant Pharmaceuticals International, Inc
Zogenix
GW Pharmaceuticals
Insys
Zynerba
Anti-epileptic Drugs for Pediatrics Breakdown Data by Type
1st generation
2nd generation
3rd generation
Anti-epileptic Drugs for Pediatrics Breakdown Data by Application
Hospitals
Retail pharmacies
Online pharmacies
Regional and Country-level Analysis
The Anti-epileptic Drugs for Pediatrics market is analysed and market size information is provided by regions (countries).
The key regions covered in the Anti-epileptic Drugs for Pediatrics market report are North America, Europe, China and Japan. It also covers key regions (countries), viz, the U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of production capacity, price and revenue for the period 2015-2026.
Competitive Landscape and Anti-epileptic Drugs for Pediatrics Market Share Analysis
Market Analysis and Insights: Global Anti-epileptic Drugs for Pediatrics Market
Prior to COVID-19, the market for Anti-epileptic Drugs for Pediatrics was anticipated to grow from US$ XX million in 2020 to US$ XX million by 2026; it is expected to grow at a CAGR of XX% during 2021–2026, whereas post-COVID-19 scenario, the market for Anti-epileptic Drugs for Pediatrics is projected to grow from US$ XX million in 2020 (a change by ~XX% compared to market estimated for 2020 before the outbreak of COVID-19) to US$ XX billion by 2026; it is expected to grow at a CAGR of XX% during 2021–2026. The solicitation of proposals by the governments and public–private companies across the world to mitigate the impact of the COVID-19 pandemic is the key factor propelling the growth of the Anti-epileptic Drugs for Pediatrics market.
Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost 200 countries around the globe with the World Health Organization declaring it a public health emergency. The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the Anti-epileptic Drugs for Pediatrics market in 2020. The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor events restricted; over forty countries state of emergency declared; massive slowing of the supply chain; stock market volatility; falling business confidence, growing panic among the population, and uncertainty about future.
This report also analyzes the impact of Coronavirus COVID-19 on the Anti-epileptic Drugs for Pediatrics industry.
Global Anti-epileptic Drugs for Pediatrics Scope and Segment
Anti-epileptic Drugs for Pediatrics market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Anti-epileptic Drugs for Pediatrics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on production capacity, revenue and forecast by Type and by Application for the period 2015-2026.
The following manufacturers are covered in this report:
Mylan N.V
Cephalon, Inc
GlaxoSmithKline plc
Janssen Pharmaceuticals
Novartis AG
Pfizer, Inc
Sanofi S.A
UCB Pharma Limited
Sunovion Pharmaceuticals Limited
Valeant Pharmaceuticals International, Inc
Zogenix
GW Pharmaceuticals
Insys
Zynerba
Anti-epileptic Drugs for Pediatrics Breakdown Data by Type
1st generation
2nd generation
3rd generation
Anti-epileptic Drugs for Pediatrics Breakdown Data by Application
Hospitals
Retail pharmacies
Online pharmacies
Regional and Country-level Analysis
The Anti-epileptic Drugs for Pediatrics market is analysed and market size information is provided by regions (countries).
The key regions covered in the Anti-epileptic Drugs for Pediatrics market report are North America, Europe, China and Japan. It also covers key regions (countries), viz, the U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of production capacity, price and revenue for the period 2015-2026.
Competitive Landscape and Anti-epileptic Drugs for Pediatrics Market Share Analysis
1 Study Coverage
1.1 Anti-epileptic Drugs for Pediatrics Product Introduction
1.2 Market Segments
1.3 Key Anti-epileptic Drugs for Pediatrics Manufacturers Covered: Ranking by Revenue
1.4 Market by Type
1.4.1 Global Anti-epileptic Drugs for Pediatrics Market Size Growth Rate by Type
1.4.2 1st generation
1.4.3 2nd generation
1.4.4 3rd generation
1.5 Market by Application
1.5.1 Global Anti-epileptic Drugs for Pediatrics Market Size Growth Rate by Application
1.5.2 Hospitals
1.5.3 Retail pharmacies
1.5.4 Online pharmacies
1.6 Study Objectives
1.7 Years Considered
2 Executive Summary
2.1 Global Anti-epileptic Drugs for Pediatrics Market Size, Estimates and Forecasts
2.1.1 Global Anti-epileptic Drugs for Pediatrics Revenue 2015-2026
2.1.2 Global Anti-epileptic Drugs for Pediatrics Sales 2015-2026
2.2 Global Anti-epileptic Drugs for Pediatrics, Market Size by Producing Regions: 2015 VS 2020 VS 2026
2.2.1 Global Anti-epileptic Drugs for Pediatrics Retrospective Market Scenario in Sales by Region: 2015-2020
2.2.2 Global Anti-epileptic Drugs for Pediatrics Retrospective Market Scenario in Revenue by Region: 2015-2020
3 Global Anti-epileptic Drugs for Pediatrics Competitor Landscape by Players
3.1 Anti-epileptic Drugs for Pediatrics Sales by Manufacturers
3.1.1 Anti-epileptic Drugs for Pediatrics Sales by Manufacturers (2015-2020)
3.1.2 Anti-epileptic Drugs for Pediatrics Sales Market Share by Manufacturers (2015-2020)
3.2 Anti-epileptic Drugs for Pediatrics Revenue by Manufacturers
3.2.1 Anti-epileptic Drugs for Pediatrics Revenue by Manufacturers (2015-2020)
3.2.2 Anti-epileptic Drugs for Pediatrics Revenue Share by Manufacturers (2015-2020)
3.2.3 Global Anti-epileptic Drugs for Pediatrics Market Concentration Ratio (CR5 and HHI) (2015-2020)
3.2.4 Global Top 10 and Top 5 Companies by Anti-epileptic Drugs for Pediatrics Revenue in 2019
3.2.5 Global Anti-epileptic Drugs for Pediatrics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Anti-epileptic Drugs for Pediatrics Price by Manufacturers
3.4 Anti-epileptic Drugs for Pediatrics Manufacturing Base Distribution, Product Types
3.4.1 Anti-epileptic Drugs for Pediatrics Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Anti-epileptic Drugs for Pediatrics Product Type
3.4.3 Date of International Manufacturers Enter into Anti-epileptic Drugs for Pediatrics Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Anti-epileptic Drugs for Pediatrics Market Size by Type (2015-2020)
4.1.1 Global Anti-epileptic Drugs for Pediatrics Sales by Type (2015-2020)
4.1.2 Global Anti-epileptic Drugs for Pediatrics Revenue by Type (2015-2020)
4.1.3 Anti-epileptic Drugs for Pediatrics Average Selling Price (ASP) by Type (2015-2026)
4.2 Global Anti-epileptic Drugs for Pediatrics Market Size Forecast by Type (2021-2026)
4.2.1 Global Anti-epileptic Drugs for Pediatrics Sales Forecast by Type (2021-2026)
4.2.2 Global Anti-epileptic Drugs for Pediatrics Revenue Forecast by Type (2021-2026)
4.2.3 Anti-epileptic Drugs for Pediatrics Average Selling Price (ASP) Forecast by Type (2021-2026)
4.3 Global Anti-epileptic Drugs for Pediatrics Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End
5 Market Size by Application (2015-2026)
5.1 Global Anti-epileptic Drugs for Pediatrics Market Size by Application (2015-2020)
5.1.1 Global Anti-epileptic Drugs for Pediatrics Sales by Application (2015-2020)
5.1.2 Global Anti-epileptic Drugs for Pediatrics Revenue by Application (2015-2020)
5.1.3 Anti-epileptic Drugs for Pediatrics Price by Application (2015-2020)
5.2 Anti-epileptic Drugs for Pediatrics Market Size Forecast by Application (2021-2026)
5.2.1 Global Anti-epileptic Drugs for Pediatrics Sales Forecast by Application (2021-2026)
5.2.2 Global Anti-epileptic Drugs for Pediatrics Revenue Forecast by Application (2021-2026)
5.2.3 Global Anti-epileptic Drugs for Pediatrics Price Forecast by Application (2021-2026)
6 North America
6.1 North America Anti-epileptic Drugs for Pediatrics by Country
6.1.1 North America Anti-epileptic Drugs for Pediatrics Sales by Country
6.1.2 North America Anti-epileptic Drugs for Pediatrics Revenue by Country
6.1.3 U.S.
6.1.4 Canada
6.2 North America Anti-epileptic Drugs for Pediatrics Market Facts & Figures by Type
6.3 North America Anti-epileptic Drugs for Pediatrics Market Facts & Figures by Application
7 Europe
7.1 Europe Anti-epileptic Drugs for Pediatrics by Country
7.1.1 Europe Anti-epileptic Drugs for Pediatrics Sales by Country
7.1.2 Europe Anti-epileptic Drugs for Pediatrics Revenue by Country
7.1.3 Germany
7.1.4 France
7.1.5 U.K.
7.1.6 Italy
7.1.7 Russia
7.2 Europe Anti-epileptic Drugs for Pediatrics Market Facts & Figures by Type
7.3 Europe Anti-epileptic Drugs for Pediatrics Market Facts & Figures by Application
8 Asia Pacific
8.1 Asia Pacific Anti-epileptic Drugs for Pediatrics by Region
8.1.1 Asia Pacific Anti-epileptic Drugs for Pediatrics Sales by Region
8.1.2 Asia Pacific Anti-epileptic Drugs for Pediatrics Revenue by Region
8.1.3 China
8.1.4 Japan
8.1.5 South Korea
8.1.6 India
8.1.7 Australia
8.1.8 Taiwan
8.1.9 Indonesia
8.1.10 Thailand
8.1.11 Malaysia
8.1.12 Philippines
8.1.13 Vietnam
8.2 Asia Pacific Anti-epileptic Drugs for Pediatrics Market Facts & Figures by Type
8.3 Asia Pacific Anti-epileptic Drugs for Pediatrics Market Facts & Figures by Application
9 Latin America
9.1 Latin America Anti-epileptic Drugs for Pediatrics by Country
9.1.1 Latin America Anti-epileptic Drugs for Pediatrics Sales by Country
9.1.2 Latin America Anti-epileptic Drugs for Pediatrics Revenue by Country
9.1.3 Mexico
9.1.4 Brazil
9.1.5 Argentina
9.2 Central & South America Anti-epileptic Drugs for Pediatrics Market Facts & Figures by Type
9.3 Central & South America Anti-epileptic Drugs for Pediatrics Market Facts & Figures by Application
10 Middle East and Africa
10.1 Middle East and Africa Anti-epileptic Drugs for Pediatrics by Country
10.1.1 Middle East and Africa Anti-epileptic Drugs for Pediatrics Sales by Country
10.1.2 Middle East and Africa Anti-epileptic Drugs for Pediatrics Revenue by Country
10.1.3 Turkey
10.1.4 Saudi Arabia
10.1.5 U.A.E
10.2 Middle East and Africa Anti-epileptic Drugs for Pediatrics Market Facts & Figures by Type
10.3 Middle East and Africa Anti-epileptic Drugs for Pediatrics Market Facts & Figures by Application
11 Company Profiles
11.1 Mylan N.V
11.1.1 Mylan N.V Corporation Information
11.1.2 Mylan N.V Description and Business Overview
11.1.3 Mylan N.V Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Mylan N.V Anti-epileptic Drugs for Pediatrics Products Offered
11.1.5 Mylan N.V Related Developments
11.2 Cephalon, Inc
11.2.1 Cephalon, Inc Corporation Information
11.2.2 Cephalon, Inc Description and Business Overview
11.2.3 Cephalon, Inc Sales, Revenue and Gross Margin (2015-2020)
11.2.4 Cephalon, Inc Anti-epileptic Drugs for Pediatrics Products Offered
11.2.5 Cephalon, Inc Related Developments
11.3 GlaxoSmithKline plc
11.3.1 GlaxoSmithKline plc Corporation Information
11.3.2 GlaxoSmithKline plc Description and Business Overview
11.3.3 GlaxoSmithKline plc Sales, Revenue and Gross Margin (2015-2020)
11.3.4 GlaxoSmithKline plc Anti-epileptic Drugs for Pediatrics Products Offered
11.3.5 GlaxoSmithKline plc Related Developments
11.4 Janssen Pharmaceuticals
11.4.1 Janssen Pharmaceuticals Corporation Information
11.4.2 Janssen Pharmaceuticals Description and Business Overview
11.4.3 Janssen Pharmaceuticals Sales, Revenue and Gross Margin (2015-2020)
11.4.4 Janssen Pharmaceuticals Anti-epileptic Drugs for Pediatrics Products Offered
11.4.5 Janssen Pharmaceuticals Related Developments
11.5 Novartis AG
11.5.1 Novartis AG Corporation Information
11.5.2 Novartis AG Description and Business Overview
11.5.3 Novartis AG Sales, Revenue and Gross Margin (2015-2020)
11.5.4 Novartis AG Anti-epileptic Drugs for Pediatrics Products Offered
11.5.5 Novartis AG Related Developments
11.6 Pfizer, Inc
11.6.1 Pfizer, Inc Corporation Information
11.6.2 Pfizer, Inc Description and Business Overview
11.6.3 Pfizer, Inc Sales, Revenue and Gross Margin (2015-2020)
11.6.4 Pfizer, Inc Anti-epileptic Drugs for Pediatrics Products Offered
11.6.5 Pfizer, Inc Related Developments
11.7 Sanofi S.A
11.7.1 Sanofi S.A Corporation Information
11.7.2 Sanofi S.A Description and Business Overview
11.7.3 Sanofi S.A Sales, Revenue and Gross Margin (2015-2020)
11.7.4 Sanofi S.A Anti-epileptic Drugs for Pediatrics Products Offered
11.7.5 Sanofi S.A Related Developments
11.8 UCB Pharma Limited
11.8.1 UCB Pharma Limited Corporation Information
11.8.2 UCB Pharma Limited Description and Business Overview
11.8.3 UCB Pharma Limited Sales, Revenue and Gross Margin (2015-2020)
11.8.4 UCB Pharma Limited Anti-epileptic Drugs for Pediatrics Products Offered
11.8.5 UCB Pharma Limited Related Developments
11.9 Sunovion Pharmaceuticals Limited
11.9.1 Sunovion Pharmaceuticals Limited Corporation Information
11.9.2 Sunovion Pharmaceuticals Limited Description and Business Overview
11.9.3 Sunovion Pharmaceuticals Limited Sales, Revenue and Gross Margin (2015-2020)
11.9.4 Sunovion Pharmaceuticals Limited Anti-epileptic Drugs for Pediatrics Products Offered
11.9.5 Sunovion Pharmaceuticals Limited Related Developments
11.10 Valeant Pharmaceuticals International, Inc
11.10.1 Valeant Pharmaceuticals International, Inc Corporation Information
11.10.2 Valeant Pharmaceuticals International, Inc Description and Business Overview
11.10.3 Valeant Pharmaceuticals International, Inc Sales, Revenue and Gross Margin (2015-2020)
11.10.4 Valeant Pharmaceuticals International, Inc Anti-epileptic Drugs for Pediatrics Products Offered
11.10.5 Valeant Pharmaceuticals International, Inc Related Developments
11.1 Mylan N.V
11.1.1 Mylan N.V Corporation Information
11.1.2 Mylan N.V Description and Business Overview
11.1.3 Mylan N.V Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Mylan N.V Anti-epileptic Drugs for Pediatrics Products Offered
11.1.5 Mylan N.V Related Developments
11.12 GW Pharmaceuticals
11.12.1 GW Pharmaceuticals Corporation Information
11.12.2 GW Pharmaceuticals Description and Business Overview
11.12.3 GW Pharmaceuticals Sales, Revenue and Gross Margin (2015-2020)
11.12.4 GW Pharmaceuticals Products Offered
11.12.5 GW Pharmaceuticals Related Developments
11.13 Insys
11.13.1 Insys Corporation Information
11.13.2 Insys Description and Business Overview
11.13.3 Insys Sales, Revenue and Gross Margin (2015-2020)
11.13.4 Insys Products Offered
11.13.5 Insys Related Developments
11.14 Zynerba
11.14.1 Zynerba Corporation Information
11.14.2 Zynerba Description and Business Overview
11.14.3 Zynerba Sales, Revenue and Gross Margin (2015-2020)
11.14.4 Zynerba Products Offered
11.14.5 Zynerba Related Developments
12 Future Forecast by Regions (Countries) (2021-2026)
12.1 Anti-epileptic Drugs for Pediatrics Market Estimates and Projections by Region
12.1.1 Global Anti-epileptic Drugs for Pediatrics Sales Forecast by Regions 2021-2026
12.1.2 Global Anti-epileptic Drugs for Pediatrics Revenue Forecast by Regions 2021-2026
12.2 North America Anti-epileptic Drugs for Pediatrics Market Size Forecast (2021-2026)
12.2.1 North America: Anti-epileptic Drugs for Pediatrics Sales Forecast (2021-2026)
12.2.2 North America: Anti-epileptic Drugs for Pediatrics Revenue Forecast (2021-2026)
12.2.3 North America: Anti-epileptic Drugs for Pediatrics Market Size Forecast by Country (2021-2026)
12.3 Europe Anti-epileptic Drugs for Pediatrics Market Size Forecast (2021-2026)
12.3.1 Europe: Anti-epileptic Drugs for Pediatrics Sales Forecast (2021-2026)
12.3.2 Europe: Anti-epileptic Drugs for Pediatrics Revenue Forecast (2021-2026)
12.3.3 Europe: Anti-epileptic Drugs for Pediatrics Market Size Forecast by Country (2021-2026)
12.4 Asia Pacific Anti-epileptic Drugs for Pediatrics Market Size Forecast (2021-2026)
12.4.1 Asia Pacific: Anti-epileptic Drugs for Pediatrics Sales Forecast (2021-2026)
12.4.2 Asia Pacific: Anti-epileptic Drugs for Pediatrics Revenue Forecast (2021-2026)
12.4.3 Asia Pacific: Anti-epileptic Drugs for Pediatrics Market Size Forecast by Region (2021-2026)
12.5 Latin America Anti-epileptic Drugs for Pediatrics Market Size Forecast (2021-2026)
12.5.1 Latin America: Anti-epileptic Drugs for Pediatrics Sales Forecast (2021-2026)
12.5.2 Latin America: Anti-epileptic Drugs for Pediatrics Revenue Forecast (2021-2026)
12.5.3 Latin America: Anti-epileptic Drugs for Pediatrics Market Size Forecast by Country (2021-2026)
12.6 Middle East and Africa Anti-epileptic Drugs for Pediatrics Market Size Forecast (2021-2026)
12.6.1 Middle East and Africa: Anti-epileptic Drugs for Pediatrics Sales Forecast (2021-2026)
12.6.2 Middle East and Africa: Anti-epileptic Drugs for Pediatrics Revenue Forecast (2021-2026)
12.6.3 Middle East and Africa: Anti-epileptic Drugs for Pediatrics Market Size Forecast by Country (2021-2026)
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Porter's Five Forces Analysis
13.5 Primary Interviews with Key Anti-epileptic Drugs for Pediatrics Players (Opinion Leaders)
14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Anti-epileptic Drugs for Pediatrics Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer
1.1 Anti-epileptic Drugs for Pediatrics Product Introduction
1.2 Market Segments
1.3 Key Anti-epileptic Drugs for Pediatrics Manufacturers Covered: Ranking by Revenue
1.4 Market by Type
1.4.1 Global Anti-epileptic Drugs for Pediatrics Market Size Growth Rate by Type
1.4.2 1st generation
1.4.3 2nd generation
1.4.4 3rd generation
1.5 Market by Application
1.5.1 Global Anti-epileptic Drugs for Pediatrics Market Size Growth Rate by Application
1.5.2 Hospitals
1.5.3 Retail pharmacies
1.5.4 Online pharmacies
1.6 Study Objectives
1.7 Years Considered
2 Executive Summary
2.1 Global Anti-epileptic Drugs for Pediatrics Market Size, Estimates and Forecasts
2.1.1 Global Anti-epileptic Drugs for Pediatrics Revenue 2015-2026
2.1.2 Global Anti-epileptic Drugs for Pediatrics Sales 2015-2026
2.2 Global Anti-epileptic Drugs for Pediatrics, Market Size by Producing Regions: 2015 VS 2020 VS 2026
2.2.1 Global Anti-epileptic Drugs for Pediatrics Retrospective Market Scenario in Sales by Region: 2015-2020
2.2.2 Global Anti-epileptic Drugs for Pediatrics Retrospective Market Scenario in Revenue by Region: 2015-2020
3 Global Anti-epileptic Drugs for Pediatrics Competitor Landscape by Players
3.1 Anti-epileptic Drugs for Pediatrics Sales by Manufacturers
3.1.1 Anti-epileptic Drugs for Pediatrics Sales by Manufacturers (2015-2020)
3.1.2 Anti-epileptic Drugs for Pediatrics Sales Market Share by Manufacturers (2015-2020)
3.2 Anti-epileptic Drugs for Pediatrics Revenue by Manufacturers
3.2.1 Anti-epileptic Drugs for Pediatrics Revenue by Manufacturers (2015-2020)
3.2.2 Anti-epileptic Drugs for Pediatrics Revenue Share by Manufacturers (2015-2020)
3.2.3 Global Anti-epileptic Drugs for Pediatrics Market Concentration Ratio (CR5 and HHI) (2015-2020)
3.2.4 Global Top 10 and Top 5 Companies by Anti-epileptic Drugs for Pediatrics Revenue in 2019
3.2.5 Global Anti-epileptic Drugs for Pediatrics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Anti-epileptic Drugs for Pediatrics Price by Manufacturers
3.4 Anti-epileptic Drugs for Pediatrics Manufacturing Base Distribution, Product Types
3.4.1 Anti-epileptic Drugs for Pediatrics Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Anti-epileptic Drugs for Pediatrics Product Type
3.4.3 Date of International Manufacturers Enter into Anti-epileptic Drugs for Pediatrics Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Anti-epileptic Drugs for Pediatrics Market Size by Type (2015-2020)
4.1.1 Global Anti-epileptic Drugs for Pediatrics Sales by Type (2015-2020)
4.1.2 Global Anti-epileptic Drugs for Pediatrics Revenue by Type (2015-2020)
4.1.3 Anti-epileptic Drugs for Pediatrics Average Selling Price (ASP) by Type (2015-2026)
4.2 Global Anti-epileptic Drugs for Pediatrics Market Size Forecast by Type (2021-2026)
4.2.1 Global Anti-epileptic Drugs for Pediatrics Sales Forecast by Type (2021-2026)
4.2.2 Global Anti-epileptic Drugs for Pediatrics Revenue Forecast by Type (2021-2026)
4.2.3 Anti-epileptic Drugs for Pediatrics Average Selling Price (ASP) Forecast by Type (2021-2026)
4.3 Global Anti-epileptic Drugs for Pediatrics Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End
5 Market Size by Application (2015-2026)
5.1 Global Anti-epileptic Drugs for Pediatrics Market Size by Application (2015-2020)
5.1.1 Global Anti-epileptic Drugs for Pediatrics Sales by Application (2015-2020)
5.1.2 Global Anti-epileptic Drugs for Pediatrics Revenue by Application (2015-2020)
5.1.3 Anti-epileptic Drugs for Pediatrics Price by Application (2015-2020)
5.2 Anti-epileptic Drugs for Pediatrics Market Size Forecast by Application (2021-2026)
5.2.1 Global Anti-epileptic Drugs for Pediatrics Sales Forecast by Application (2021-2026)
5.2.2 Global Anti-epileptic Drugs for Pediatrics Revenue Forecast by Application (2021-2026)
5.2.3 Global Anti-epileptic Drugs for Pediatrics Price Forecast by Application (2021-2026)
6 North America
6.1 North America Anti-epileptic Drugs for Pediatrics by Country
6.1.1 North America Anti-epileptic Drugs for Pediatrics Sales by Country
6.1.2 North America Anti-epileptic Drugs for Pediatrics Revenue by Country
6.1.3 U.S.
6.1.4 Canada
6.2 North America Anti-epileptic Drugs for Pediatrics Market Facts & Figures by Type
6.3 North America Anti-epileptic Drugs for Pediatrics Market Facts & Figures by Application
7 Europe
7.1 Europe Anti-epileptic Drugs for Pediatrics by Country
7.1.1 Europe Anti-epileptic Drugs for Pediatrics Sales by Country
7.1.2 Europe Anti-epileptic Drugs for Pediatrics Revenue by Country
7.1.3 Germany
7.1.4 France
7.1.5 U.K.
7.1.6 Italy
7.1.7 Russia
7.2 Europe Anti-epileptic Drugs for Pediatrics Market Facts & Figures by Type
7.3 Europe Anti-epileptic Drugs for Pediatrics Market Facts & Figures by Application
8 Asia Pacific
8.1 Asia Pacific Anti-epileptic Drugs for Pediatrics by Region
8.1.1 Asia Pacific Anti-epileptic Drugs for Pediatrics Sales by Region
8.1.2 Asia Pacific Anti-epileptic Drugs for Pediatrics Revenue by Region
8.1.3 China
8.1.4 Japan
8.1.5 South Korea
8.1.6 India
8.1.7 Australia
8.1.8 Taiwan
8.1.9 Indonesia
8.1.10 Thailand
8.1.11 Malaysia
8.1.12 Philippines
8.1.13 Vietnam
8.2 Asia Pacific Anti-epileptic Drugs for Pediatrics Market Facts & Figures by Type
8.3 Asia Pacific Anti-epileptic Drugs for Pediatrics Market Facts & Figures by Application
9 Latin America
9.1 Latin America Anti-epileptic Drugs for Pediatrics by Country
9.1.1 Latin America Anti-epileptic Drugs for Pediatrics Sales by Country
9.1.2 Latin America Anti-epileptic Drugs for Pediatrics Revenue by Country
9.1.3 Mexico
9.1.4 Brazil
9.1.5 Argentina
9.2 Central & South America Anti-epileptic Drugs for Pediatrics Market Facts & Figures by Type
9.3 Central & South America Anti-epileptic Drugs for Pediatrics Market Facts & Figures by Application
10 Middle East and Africa
10.1 Middle East and Africa Anti-epileptic Drugs for Pediatrics by Country
10.1.1 Middle East and Africa Anti-epileptic Drugs for Pediatrics Sales by Country
10.1.2 Middle East and Africa Anti-epileptic Drugs for Pediatrics Revenue by Country
10.1.3 Turkey
10.1.4 Saudi Arabia
10.1.5 U.A.E
10.2 Middle East and Africa Anti-epileptic Drugs for Pediatrics Market Facts & Figures by Type
10.3 Middle East and Africa Anti-epileptic Drugs for Pediatrics Market Facts & Figures by Application
11 Company Profiles
11.1 Mylan N.V
11.1.1 Mylan N.V Corporation Information
11.1.2 Mylan N.V Description and Business Overview
11.1.3 Mylan N.V Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Mylan N.V Anti-epileptic Drugs for Pediatrics Products Offered
11.1.5 Mylan N.V Related Developments
11.2 Cephalon, Inc
11.2.1 Cephalon, Inc Corporation Information
11.2.2 Cephalon, Inc Description and Business Overview
11.2.3 Cephalon, Inc Sales, Revenue and Gross Margin (2015-2020)
11.2.4 Cephalon, Inc Anti-epileptic Drugs for Pediatrics Products Offered
11.2.5 Cephalon, Inc Related Developments
11.3 GlaxoSmithKline plc
11.3.1 GlaxoSmithKline plc Corporation Information
11.3.2 GlaxoSmithKline plc Description and Business Overview
11.3.3 GlaxoSmithKline plc Sales, Revenue and Gross Margin (2015-2020)
11.3.4 GlaxoSmithKline plc Anti-epileptic Drugs for Pediatrics Products Offered
11.3.5 GlaxoSmithKline plc Related Developments
11.4 Janssen Pharmaceuticals
11.4.1 Janssen Pharmaceuticals Corporation Information
11.4.2 Janssen Pharmaceuticals Description and Business Overview
11.4.3 Janssen Pharmaceuticals Sales, Revenue and Gross Margin (2015-2020)
11.4.4 Janssen Pharmaceuticals Anti-epileptic Drugs for Pediatrics Products Offered
11.4.5 Janssen Pharmaceuticals Related Developments
11.5 Novartis AG
11.5.1 Novartis AG Corporation Information
11.5.2 Novartis AG Description and Business Overview
11.5.3 Novartis AG Sales, Revenue and Gross Margin (2015-2020)
11.5.4 Novartis AG Anti-epileptic Drugs for Pediatrics Products Offered
11.5.5 Novartis AG Related Developments
11.6 Pfizer, Inc
11.6.1 Pfizer, Inc Corporation Information
11.6.2 Pfizer, Inc Description and Business Overview
11.6.3 Pfizer, Inc Sales, Revenue and Gross Margin (2015-2020)
11.6.4 Pfizer, Inc Anti-epileptic Drugs for Pediatrics Products Offered
11.6.5 Pfizer, Inc Related Developments
11.7 Sanofi S.A
11.7.1 Sanofi S.A Corporation Information
11.7.2 Sanofi S.A Description and Business Overview
11.7.3 Sanofi S.A Sales, Revenue and Gross Margin (2015-2020)
11.7.4 Sanofi S.A Anti-epileptic Drugs for Pediatrics Products Offered
11.7.5 Sanofi S.A Related Developments
11.8 UCB Pharma Limited
11.8.1 UCB Pharma Limited Corporation Information
11.8.2 UCB Pharma Limited Description and Business Overview
11.8.3 UCB Pharma Limited Sales, Revenue and Gross Margin (2015-2020)
11.8.4 UCB Pharma Limited Anti-epileptic Drugs for Pediatrics Products Offered
11.8.5 UCB Pharma Limited Related Developments
11.9 Sunovion Pharmaceuticals Limited
11.9.1 Sunovion Pharmaceuticals Limited Corporation Information
11.9.2 Sunovion Pharmaceuticals Limited Description and Business Overview
11.9.3 Sunovion Pharmaceuticals Limited Sales, Revenue and Gross Margin (2015-2020)
11.9.4 Sunovion Pharmaceuticals Limited Anti-epileptic Drugs for Pediatrics Products Offered
11.9.5 Sunovion Pharmaceuticals Limited Related Developments
11.10 Valeant Pharmaceuticals International, Inc
11.10.1 Valeant Pharmaceuticals International, Inc Corporation Information
11.10.2 Valeant Pharmaceuticals International, Inc Description and Business Overview
11.10.3 Valeant Pharmaceuticals International, Inc Sales, Revenue and Gross Margin (2015-2020)
11.10.4 Valeant Pharmaceuticals International, Inc Anti-epileptic Drugs for Pediatrics Products Offered
11.10.5 Valeant Pharmaceuticals International, Inc Related Developments
11.1 Mylan N.V
11.1.1 Mylan N.V Corporation Information
11.1.2 Mylan N.V Description and Business Overview
11.1.3 Mylan N.V Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Mylan N.V Anti-epileptic Drugs for Pediatrics Products Offered
11.1.5 Mylan N.V Related Developments
11.12 GW Pharmaceuticals
11.12.1 GW Pharmaceuticals Corporation Information
11.12.2 GW Pharmaceuticals Description and Business Overview
11.12.3 GW Pharmaceuticals Sales, Revenue and Gross Margin (2015-2020)
11.12.4 GW Pharmaceuticals Products Offered
11.12.5 GW Pharmaceuticals Related Developments
11.13 Insys
11.13.1 Insys Corporation Information
11.13.2 Insys Description and Business Overview
11.13.3 Insys Sales, Revenue and Gross Margin (2015-2020)
11.13.4 Insys Products Offered
11.13.5 Insys Related Developments
11.14 Zynerba
11.14.1 Zynerba Corporation Information
11.14.2 Zynerba Description and Business Overview
11.14.3 Zynerba Sales, Revenue and Gross Margin (2015-2020)
11.14.4 Zynerba Products Offered
11.14.5 Zynerba Related Developments
12 Future Forecast by Regions (Countries) (2021-2026)
12.1 Anti-epileptic Drugs for Pediatrics Market Estimates and Projections by Region
12.1.1 Global Anti-epileptic Drugs for Pediatrics Sales Forecast by Regions 2021-2026
12.1.2 Global Anti-epileptic Drugs for Pediatrics Revenue Forecast by Regions 2021-2026
12.2 North America Anti-epileptic Drugs for Pediatrics Market Size Forecast (2021-2026)
12.2.1 North America: Anti-epileptic Drugs for Pediatrics Sales Forecast (2021-2026)
12.2.2 North America: Anti-epileptic Drugs for Pediatrics Revenue Forecast (2021-2026)
12.2.3 North America: Anti-epileptic Drugs for Pediatrics Market Size Forecast by Country (2021-2026)
12.3 Europe Anti-epileptic Drugs for Pediatrics Market Size Forecast (2021-2026)
12.3.1 Europe: Anti-epileptic Drugs for Pediatrics Sales Forecast (2021-2026)
12.3.2 Europe: Anti-epileptic Drugs for Pediatrics Revenue Forecast (2021-2026)
12.3.3 Europe: Anti-epileptic Drugs for Pediatrics Market Size Forecast by Country (2021-2026)
12.4 Asia Pacific Anti-epileptic Drugs for Pediatrics Market Size Forecast (2021-2026)
12.4.1 Asia Pacific: Anti-epileptic Drugs for Pediatrics Sales Forecast (2021-2026)
12.4.2 Asia Pacific: Anti-epileptic Drugs for Pediatrics Revenue Forecast (2021-2026)
12.4.3 Asia Pacific: Anti-epileptic Drugs for Pediatrics Market Size Forecast by Region (2021-2026)
12.5 Latin America Anti-epileptic Drugs for Pediatrics Market Size Forecast (2021-2026)
12.5.1 Latin America: Anti-epileptic Drugs for Pediatrics Sales Forecast (2021-2026)
12.5.2 Latin America: Anti-epileptic Drugs for Pediatrics Revenue Forecast (2021-2026)
12.5.3 Latin America: Anti-epileptic Drugs for Pediatrics Market Size Forecast by Country (2021-2026)
12.6 Middle East and Africa Anti-epileptic Drugs for Pediatrics Market Size Forecast (2021-2026)
12.6.1 Middle East and Africa: Anti-epileptic Drugs for Pediatrics Sales Forecast (2021-2026)
12.6.2 Middle East and Africa: Anti-epileptic Drugs for Pediatrics Revenue Forecast (2021-2026)
12.6.3 Middle East and Africa: Anti-epileptic Drugs for Pediatrics Market Size Forecast by Country (2021-2026)
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Porter's Five Forces Analysis
13.5 Primary Interviews with Key Anti-epileptic Drugs for Pediatrics Players (Opinion Leaders)
14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Anti-epileptic Drugs for Pediatrics Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer
